bioMerieux

BIM.PAPre-clinical

bioMérieux SA is a leading global diagnostics company headquartered in Marcy-l'Étoile, France, with over 13,000 employees worldwide. The company operates across three main business segments: clinical diagnostics (microbiology, immunoassays, molecular biology), industrial applications (food safety, pharmaceutical quality control), and emerging markets including point-of-care testing. With a strong focus on innovation and R&D investment of approximately 12% of sales, bioMérieux serves customers in over 160 countries through a comprehensive portfolio of diagnostic solutions.

Market Cap

$12.4B

Employees

13,000+

Focus

Biotech

BIM.PA · Stock Price

USD 90.70+2.16 (+2.44%)

Historical price data

AI Company Overview

Technology Platform

Comprehensive in vitro diagnostics platform encompassing microbiology (VITEK®), immunoassays (VIDAS®), and molecular biology (FilmArray®) for rapid identification of pathogens and antimicrobial resistance patterns.

Opportunities

Significant growth opportunities in point-of-care testing, syndromic panels expansion, emerging markets penetration, and digital health integration.

The company is well-positioned to benefit from increased focus on antimicrobial resistance and pandemic preparedness initiatives globally.

Risk Factors

Key risks include intense competition from larger diagnostics companies, regulatory and reimbursement pressures, potential technology disruption from new diagnostic modalities, and supply chain vulnerabilities.

Currency fluctuations and economic uncertainties in key markets also pose challenges.

Competitive Landscape

bioMérieux competes with major players including Abbott, Roche Diagnostics, Siemens Healthineers, and Becton Dickinson in the global IVD market. The company differentiates through its strong microbiology expertise, comprehensive syndromic testing solutions, and BIOFIRE® platform leadership in multiplex PCR diagnostics.

Publications

Patents